Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Cancer Liver Metastases
NCT07815288Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in colorectal adenocarcinoma, sponsored by Peking University Cancer Hospital & Institute. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT07815288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815288.